Skip to menu Skip to content Skip to footer
Associate Professor

Simone M Goldinger

Email: 

Overview

Availability

Associate Professor Simone M Goldinger is:
Available for supervision

Qualifications

  • Bachelor (Honours) of Medicine, University of Zurich
  • Masters (Research) of Medicine and Surgery and Medical Science, University of Zurich
  • Doctoral (Research), University of Zurich
  • Professional Doctorate, University of Zurich
  • Fellow, Australasian College of Dermatologists, Australasian College of Dermatologists

Works

Search Professor Simone M Goldinger’s works on UQ eSpace

136 works between 2006 and 2025

81 - 100 of 136 works

2015

Journal Article

Acquired <i>BRAF</i> inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

Johnson, Douglas B., Menzies, Alexander M., Zimmer, Lisa, Eroglu, Zeynep, Ye, Fei, Zhao, Shilin, Rizos, Helen, Sucker, Antje, Scolyer, Richard A., Gutzmer, Ralf, Gogas, Helen, Kefford, Richard F., Thompson, John F., Becker, Juergen C., Berking, Carola, Egberts, Friederike, Loquai, Carmen, Goldinger, Simone M., Pupo, Gulietta M., Hugo, Willy, Kong, Xiangju, Garraway, Levi A., Sosman, Jeffrey A., Ribas, Antoni, Lo, Roger S., Long, Georgina V. and Schadendorf, Dirk (2015). Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. European Journal of Cancer, 51 (18), 2792-2799. doi: 10.1016/j.ejca.2015.08.022

Acquired <i>BRAF</i> inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

2015

Journal Article

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Van Allen, Eliezer M., Miao, Diana, Schilling, Bastian, Shukla, Sachet A., Blank, Christian, Zimmer, Lisa, Sucker, Antje, Hillen, Uwe, Foppen, Marnix H. Geukes, Goldinger, Simone M., Utikal, Jochen, Hassel, Jessica C., Weide, Benjamin, Kaehler, Katharina C., Loquai, Carmen, Mohr, Peter, Gutzmer, Ralf, Dummer, Reinhard, Gabriel, Stacey, Wu, Catherine J., Schadendorf, Dirk and Garraway, Levi A. (2015). Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science, 350 (6257), 207-211. doi: 10.1126/science.aad0095

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

2015

Journal Article

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

Mangana, Joanna, Cheng, Phil F., Schindler, Katja, Weide, Benjamin, Held, Ulrike, Frauchiger, Anna L., Romano, Emanuella, Kaehler, Katharina C., Rozati, Sima, Rechsteiner, Markus, Moch, Holger, Michielin, Olivier, Garbe, Claus, Hauschild, Axel, Hoeller, Christoph, Dummer, Reinhard and Goldinger, Simone M. (2015). Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. Plos One, 10 (10) e0139438. doi: 10.1371/journal.pone.0139438

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

2015

Journal Article

Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanoma

Matsushita, Shigeto, Kraehenbuehl, Lukas, Otsuka, Atsushi, Mihic-Probst, Daniela, Cheng, Phil, Dummer, Reinhard and Goldinger, Simone M. (2015). Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanoma. Journal of Dermatology, 42 (9), 927-928. doi: 10.1111/1346-8138.12964

Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanoma

2015

Journal Article

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Ribas, Antoni, Puzanov, Igor, Dummer, Reinhard, Schadendorf, Dirk, Hamid, Omid, Robert, Caroline, Hodi, F. Stephen, Schachter, Jacob, Pavlick, Anna C., Lewis, Karl D., Cranmer, Lee D., Blank, Christian U., O'Day, Steven J., Ascierto, Paolo A., Salama, April K. S., Margolin, Kim A., Loquai, Carmen, Eigentler, Thomas K., Gangadhar, Tara C., Carlino, Matteo S., Agarwala, Sanjiv S., Moschos, Stergios J., Sosman, Jeffrey A., Goldinger, Simone M., Shapira-Frommer, Ronnie, Gonzalez, Rene, Kirkwood, John M., Wolchok, Jedd D., Eggermont, Alexander ... Daud, Adil (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, 16 (8), 908-918. doi: 10.1016/S1470-2045(15)00083-2

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

2015

Journal Article

Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients

Hecht, M., Zimmer, L., Loquai, C., Weishaupt, C., Gutzmer, R., Schuster, B., Gleisner, S., Schulze, B., Goldinger, S. M., Berking, C., Forschner, A., Clemens, P., Grabenbauer, G., Mueller-Brenne, T., Bauch, J., Eich, H. T., Grabbe, S., Schadendorf, D., Schuler, G., Keikavoussi, P., Semrau, S., Fietkau, R., Distel, L. V. and Heinzerling, L. (2015). Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Annals of Oncology, 26 (6), 1238-1244. doi: 10.1093/annonc/mdv139

Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients

2015

Conference Publication

Radio Sensitization through BRAF Inhibitors- Mechanism and Frequency of Toxicities in Melanoma patients

Hecht, M., Zimmer, L., Loquai, C., Weishaupt, C., Gutzmer, R., Schuster, B., Gleisner, S., Schulze, B., Goldinger, S. M., Berking, C., Forschner, A., Clemens, P., Grabenbauer, G., Mueller-Brenne, T., Bauch, J., Eich, H. T., Grabbe, S., Schadendorf, D., Schuler, G., Keikavoussi, P., Semrau, S., Fietkau, R., Distel, L. V. and Heinzerling, L. (2015). Radio Sensitization through BRAF Inhibitors- Mechanism and Frequency of Toxicities in Melanoma patients. 21st Annual Meeting of the German-Society-for-Radiation-Oncology, Hamburg Germany, Jun 25-28, 2015. MUNICH: URBAN & VOGEL.

Radio Sensitization through BRAF Inhibitors- Mechanism and Frequency of Toxicities in Melanoma patients

2015

Conference Publication

Real life experience with check point and kinase inhibitors in Swiss advanced melanoma patients

Goldinger, Simone M., Mangana, Joanna, Frauchiger, Anna L., Kaufmann, Corina, Held, Ulrike, Von Moos, Roger, Romano, Emanuela, Michielin, Olivier, Levesque, Mitchell Paul and Dummer, Reinhard (2015). Real life experience with check point and kinase inhibitors in Swiss advanced melanoma patients. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago Il, May 29-Jun 02, 2015. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.

Real life experience with check point and kinase inhibitors in Swiss advanced melanoma patients

2015

Conference Publication

Association of PD-L1 expression in melanoma with response and prognosis to ipilimumab

Brueggemann, Caroline, Weide, Benjamin, Goldinger, Simone M., Konrad, Andreas, Erdmann, Michael, Schadendorf, Dirk, Croner, Roland S., Kraehenbuehl, Lukas, Kaehler, Katharina C., Hafner, Christian, Leisgang, Waltraud, Kiesewetter, Franklin, Dummer, Reinhard, Schuler, Gerold, Stuerzl, Michael and Heinzerling, Lucie (2015). Association of PD-L1 expression in melanoma with response and prognosis to ipilimumab. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago Il, May 29-Jun 02, 2015. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.

Association of PD-L1 expression in melanoma with response and prognosis to ipilimumab

2015

Conference Publication

A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma

Goldinger, Simone M., Gobbi, Sharon, Ding, Michelle, Frauchiger, Anna Lisa, Fink-Puches, Regina, Klemke, Claus-Detlev, Dreno, Brigitte, Bagot, Martine, Assaf, Chalid and Dummer, Reinhard (2015). A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago Il, May 29-Jun 02, 2015. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.

A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma

2015

Conference Publication

Efficacy and safety of oral alitretinoin in oral mucosal lichen planus-results of a prospective trial

Kunz, Michael, Urosevic-Maiwald, Mirjana, Cozzio, Antonio, Dippel, Michaela, Dreier, Jil, French, Lars E., Goldinger, Simone, Guenova, Emmanuella, Jenni, Daniella, Kamarachev, Jivko, Mangana, Johanna and Dummer, Reinhard (2015). Efficacy and safety of oral alitretinoin in oral mucosal lichen planus-results of a prospective trial. NEW YORK: MOSBY-ELSEVIER.

Efficacy and safety of oral alitretinoin in oral mucosal lichen planus-results of a prospective trial

2015

Conference Publication

Systemic treatments in melanoma influence the accessibility of the immune system to the tumor: A retrospective histopathological investigation

Kraehenbuehl, L., Goldinger, S. M., Matsushita, S., Amann, V. C., Kempf, W., Levesque, M. P. and Dummer, R. (2015). Systemic treatments in melanoma influence the accessibility of the immune system to the tumor: A retrospective histopathological investigation. HOBOKEN: WILEY-BLACKWELL.

Systemic treatments in melanoma influence the accessibility of the immune system to the tumor: A retrospective histopathological investigation

2015

Journal Article

Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor

Galliker, Nadja A., Murer, Carla, Kamarashev, Jivko, Dummer, Reinhard and Goldinger, Simone M. (2015). Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor. European Journal of Dermatology, 25 (2), 177-180. doi: 10.1684/ejd.2014.2512

Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor

2015

Journal Article

A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma

Goldinger, Simone M., Rinderknecht, Jeannine, Dummer, Reinhard, Kuhn, Felix Pierre, Yang, Kuo-Hsiung, Lee, Lucy, Ayala, Ruben C., Racha, Jagdish, Geng, Wanping, Moore, David, Liu, Mei, Joe, Andrew K., Bazan, Selby Patricia Gil and Grippo, Joseph F. (2015). A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. Pharmacology Research & Perspectives, 3 (2) e00113. doi: 10.1002/prp2.113

A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma

2015

Journal Article

Curing advanced melanoma by 2025

Dummer, Reinhard, Goldinger, Simone M., Paulitschke, Verena and Levesque, Mitchell P. (2015). Curing advanced melanoma by 2025. Current Opinion in Oncology, 27 (2), 125-127. doi: 10.1097/CCO.0000000000000168

Curing advanced melanoma by 2025

2015

Journal Article

Methylation-dependent <i>SOX9</i> expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma

Cheng, Phil F., Shakhova, Olga, Widmer, Daniel S., Eichhoff, Ossia M., Zingg, Daniel, Frommel, Sandra C., Belloni, Benedetta, Raaijmakers, Marieke I. G., Goldinger, Simone M., Santoro, Raffaella, Hemmi, Silvio, Sommer, Lukas, Dummer, Reinhard and Levesque, Mitchell P. (2015). Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. Genome Biology, 16 42. doi: 10.1186/s13059-015-0594-4

Methylation-dependent <i>SOX9</i> expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma

2014

Journal Article

Basal cell carcinomas in a tertiary referral centre: a systematic analysis

Dreier, J., Cheng, P. F., Alleman, I. Bogdan, Gugger, A., Hafner, J., Tschopp, A., Goldinger, S. M., Levesque, M. P. and Dummer, R. (2014). Basal cell carcinomas in a tertiary referral centre: a systematic analysis. British Journal of Dermatology, 171 (5), 1066-1072. doi: 10.1111/bjd.13217

Basal cell carcinomas in a tertiary referral centre: a systematic analysis

2014

Journal Article

Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous <i>t</i>-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome)

Dummer, R., Duvic, M., Scarisbrick, J., Olsen, E. A., Rozati, S., Eggmann, N., Goldinger, S. M., Hutchinson, K., Geskin, L., Illidge, T. M., Giuliano, E., Elder, J. and Kim, Y. H. (2014). Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome). Annals of Oncology, 25 (9), 1807-1812. doi: 10.1093/annonc/mdu231

Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous <i>t</i>-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome)

2014

Conference Publication

Association of leukocyte counts and adverse events in BRAF inhibitor-treated patients

Cosgarea, I., Sondermann, W., Livingstone, E., Griewank, K., Weide, B., Loquai, C., Hassel, J., Kaehler, K. C., Utikal, J., Al Ghazal, P., Gutzmer, R., Goldinger, S. M., Schadendorf, D., Zimmer, L. and Schilling, B. (2014). Association of leukocyte counts and adverse events in BRAF inhibitor-treated patients. HOBOKEN: WILEY-BLACKWELL.

Association of leukocyte counts and adverse events in BRAF inhibitor-treated patients

2014

Conference Publication

Immunreactivity for CTLA-4 in anterior pituitary gland cells and neutrophils suggest antibody dependent cytotoxicity to trigger Ipilimumab induced hypophysitis

Bjasch, D., Maggio, E. Marquez, Fitsche, A., Moch, H., Goldinger, S. M., Dummer, R. and Mihic-Probst, D. (2014). Immunreactivity for CTLA-4 in anterior pituitary gland cells and neutrophils suggest antibody dependent cytotoxicity to trigger Ipilimumab induced hypophysitis. NEW YORK: SPRINGER.

Immunreactivity for CTLA-4 in anterior pituitary gland cells and neutrophils suggest antibody dependent cytotoxicity to trigger Ipilimumab induced hypophysitis

Supervision

Availability

Associate Professor Simone M Goldinger is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Media

Enquiries

For media enquiries about Associate Professor Simone M Goldinger's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au